Coronary imaging: Angiography shows the stenosis, but IVUS, CT, and MRI show the plaque

**ABSTRACT**

Angiography is the standard clinical test for advanced coronary artery disease. Tomographic cardiovascular imaging tests, ie, intravascular ultrasonography (IVUS), computed tomography (CT), and magnetic resonance imaging (MRI), can be used to assess atherosclerotic plaques responsible for early, silent disease and may become important tools for early detection and prevention.

**KEY POINTS**

Selective coronary angiography is the gold standard for detecting severely stenotic lesions of the coronary lumen but does not provide information about the disease process, which takes place in the vessel wall.

Tomographic coronary imaging tests allow early, direct assessment of atherosclerotic plaques.

- IVUS is clinically well established but invasive.
- Multislice CT and MRI have great potential for noninvasive imaging of atherosclerotic plaques.

For patients with coronary artery disease, we do not yet know how much value these new imaging tests will add to traditional risk factor assessment and angiography.

**STRENGTHS AND WEAKNESSES OF ANGIOGRAPHY**

Selective coronary angiography, introduced by Dr. Mason Sones of The Cleveland Clinic Foundation in 1958, reliably identifies luminal dimension in the entire epicardial tree with high resolution. It therefore remains vital for detecting and treating severely stenotic coronary lesions, and it remains the basis for
catheter-based and surgical revascularization.

But angiography shows only the lumen, whereas coronary artery disease is a disease of the vessel wall. Typically, an angiographic study is considered positive only when stenosis is severe enough to limit flow.

We have learned that atherosclerotic plaque begins to accumulate in the arterial wall long before the lumen becomes narrowed. In fact, most acute coronary syndromes are triggered by sudden disruption of atherosclerotic plaques that caused neither significant stenosis nor angina pectoris before the event.

Because early but potentially dangerous lesions are often not associated with changes in lumen size, angiography alone does not tell the whole story.

■ ‘RUSTY PIPES’: A FLAWED ANALOGY

The angiographic appearance of severe coronary lesions led to the analogy comparing coronary disease to rusty pipes. According to this traditional, simplistic model, plaque gradually accumulates inside the vessel until it eventually obstructs the lumen and causes acute coronary events.

But this model cannot explain several observations from pathological and clinical studies.1,2

Atherosclerosis is common, but often does not cause stenosis

Necropsy studies of patients who died of noncardiac causes and IVUS examinations in heart transplant recipients have shown that atherosclerotic lesions begin to develop in childhood.

We performed IVUS in 262 heart transplant recipients weeks after they received their transplants; the donors were young, had no clinical evidence of coronary artery disease, and had died of trauma, typically motor vehicle accidents. The prevalence of coronary lesions (defined as intimal thickening > 0.5 mm by IVUS) varied from 17% in hearts from donors younger than 20 years to 85% in those 50 years and older.2,3

These findings indicate that clinical symptoms and traditional imaging techniques identify only the “tip of the atherosclerotic iceberg.”

Clinical symptoms, stress testing, and angiography are not sensitive in detecting early, silent coronary artery disease because they become positive only when accumulation of atherosclerotic plaque leads to significant, flow-limiting stenosis of the vessel lumen. However, initial plaque development frequently does not lead to stenosis.4

Mildly stenotic lesions cause most events

“Silent” coronary artery disease, although nonobstructive, is still clinically significant. In fact, angiographic studies demonstrate that most acute coronary events start with rupture or superficial erosion of mildly stenotic lesions that had not caused ischemic symptoms before.5–7 About two thirds of events arise from lesions that caused less than 50% stenosis before the event, another one sixth arise from lesions that previously caused 50% to 70% stenosis, and only about one sixth come from lesions that previously caused more than 70% stenosis.

Myocardial infarction or sudden cardiac death are the initial presentations of coronary artery disease in more than 50% of patients.

■ THE NEW MODEL OF CORONARY DISEASE

Early changes: Outward remodeling

Histologic and IVUS studies of coronary lesions show that, early on, as plaque grows, the arterial wall expands outward. This outward remodeling (also called “positive” remodeling) maintains luminal size despite plaque accumulation.8,9 These accumulating lesions, which cause minimal luminal obstruction, are often characterized as “minor luminal irregularities” by angiography.

IVUS has shown that relatively large plaques can accumulate without significant luminal stenosis. Many patients have more than one of these sites, which add up to a relatively large but asymptomatic disease burden.10

It was initially believed that outward arterial remodeling was a purely compensatory mechanism with the beneficial effect of maintaining blood flow, and that luminal stenosis and clinical disease ensued when the vessel could not expand further.8
However, several recent studies that examined the relation between arterial remodeling and clinical presentation have changed our understanding of early atherosclerotic changes in the vessel wall. Surprisingly, these studies consistently found outward remodeling to be strongly associated with unstable coronary syndromes. We compared the remodeling response in 85 patients who presented with unstable angina or acute myocardial infarction and in 46 patients with stable clinical presentations. Outward remodeling was significantly more common in the unstable group and negative remodeling, the narrowing of the lumen, was significantly more common in the stable group (FIGURE 1). In a recent prospective study of mildly stenotic lesions, Yamagishi et al found that plaques with positive remodeling at baseline more frequently led to acute coronary syndromes during follow-up.

Because of this association of outward remodeling with unstable clinical presentations, it has been suggested that the term “positive” remodeling be avoided.

A link with inflammation
A clue to the possible mechanism of the link between remodeling and unstable clinical presentation comes from histologic studies in which positive remodeling was associated with an inflammatory response at the lesion site. Inflammation is a central process in the transition from stable to unstable atheroma and in plaque progression.

A diffuse, systemic disease
In summary, in the emerging model of coronary artery disease, atherosclerotic lesions develop initially without luminal stenosis. Plaque rupture and subsequent fibrosis are likely frequent, asymptomatic events related to plaque progression.
Supporting this concept of a systemic disease process is the recent finding that plaque disruption in patients presenting with unstable coronary syndromes is not a focal phenomenon at the “culprit” lesion, but is often found at additional distant sites. Clinical acute coronary events, including unstable angina, myocardial infarction, and sudden cardiac death, are caused by plaque rupture or erosion with subsequent obstructing thrombosis and are focal manifestations of this systemic disease process.

After episodes of rupture the plaque may stabilize, eventually leading to inward remodeling (vessel shrinkage) of the coronary segment and fibrosis and calcification of the associated plaque. These changes may lead to flow-limiting lesions that are clinically symptomatic but stable.

TOMOGRAPHIC IMAGING: POTENTIAL ROLE IN SCREENING

These findings suggest that, to prevent the complications of coronary artery disease such as myocardial infarction and sudden coronary death, we probably need to diagnose and treat coronary artery disease many years before hemodynamically significant coronary stenoses develop. This is the rationale for screening for traditional risk factors such as hyperlipidemia, and there is consistent evidence that early treatment of these risk factors decreases future cardiovascular events.

Tomographic imaging tests allow direct assessment of the morphology of the vessel wall and of atherosclerotic plaque. The information these tests provide is complementary to the information provided by symptoms, stress testing, and angiography.

Could tomographic imaging play a role in detecting coronary disease early in patients with no symptoms or with only minimal symptoms? We summarize the current and emerging evidence below, but we must emphasize that the current data are not sufficient to recommend these diagnostic tests in routine clinical or general screening.

Measuring coronary calcification with CT, IVUS, and angiography

Coronary calcification is a reliable sign of atherosclerotic plaque. The extent of coronary calcification can be estimated during angiography, but CT calcium scoring is more sensitive.

Several studies showed that the CT calcium score, a measure of the overall amount of calcified plaque, correlates with, but greatly underestimates, the overall plaque burden. Nonetheless, higher scores seem to predict clinical events.

However, coronary calcifications can have different significance. In particular, the significance of small calcifications in lipid-rich plaques is unclear: they may be associated with instability, while calcification in more advanced lesions may be a stabilizing factor. It is therefore not completely clear if an increase in coronary calcifications over time is a sign of increased or decreased lesion stability. In fact, serial IVUS studies indicate that disease stabilization is associated with increasing lesion calcification.

Current guidelines recommend calcium screening only for selected patients with intermediate risk profiles and after consultation.
with a physician familiar with the concepts of preventive cardiology.\textsuperscript{39}

\textbf{IVUS can assess plaque volume, morphology}

Like carotid ultrasonography, coronary IVUS can identify calcified and noncalcified plaque and can be used to assess plaque burden in coronary vessels (\textbf{FIGURE 2}).

A recent study\textsuperscript{38} compared changes in plaque volume in a group of patients treated with a lipid-lowering medication and in a control group. The treatment group had a trend towards a smaller increase in plaque volume, but the difference was not significant. In addition, plaques in the treatment group increased in echogenicity over time, presumably reflecting morphologic changes associated with lipid depletion.

Similar, larger trials are under way. For example, the large prospective, randomized REVERSAL study\textsuperscript{40} is comparing changes in plaque volume in patients undergoing high-dose lipid-lowering treatment and in a control group. Baseline IVUS studies have already been performed in 657 patients, and matched follow-up studies after 18 months of treatment are available for most of them.

\textbf{MRI, CT are noninvasive}

IVUS, with its view from inside the artery, has high resolution, but its invasiveness limits its use in preventive settings. Needed are noninvasive imaging tests.

CT scanners have improved to the point that they can now reveal coronary atherosclerotic plaque in clinical settings (\textbf{FIGURE 3}). Several studies reported that CT with intravenous contrast could identify calcified and noncalcified coronary lesions.\textsuperscript{41} Schroeder et al\textsuperscript{42} performed IVUS and multislice CT in 15 patients undergoing percutaneous interventions. Both tests could distinguish soft, intermediate, and hard (calcified) plaque.

Similar developments can be expected with MRI.\textsuperscript{43} MRI has been used to characterize plaque in the carotid artery, and the appearance of the plaque on MRI has been correlated with clinical presentation.\textsuperscript{44,45} A recent study observed attenuated plaque progression in the aorta during lipid-lowering treatment.\textsuperscript{46}

CT and MRI have great potential, as they are noninvasive and provide comprehensive information about stenotic and nonstenotic plaque and myocardial viability.\textsuperscript{47,48} However, how much value they will add to traditional risk factor assessment and angiography has not been proven for patients with coronary artery disease.

\section*{CONCLUSION}

IVUS, CT, and MRI allow a comprehensive view of coronary anatomy and supplement the information provided by angiography. Direct assessment of the atherosclerotic plaque may in particular be important in detecting early coronary artery disease and stratifying risk in disease prevention.

While these tests are currently the focus of intense clinical research, their incremental value is not yet proven. Accordingly, their use requires a careful clinical assessment of potential risks and benefits in individual patients.

\begin{figure}
\centering
\includegraphics[width=\textwidth]{image}
\caption{Multiple areas of mild, hemodynamically insignificant stenosis of the left anterior descending coronary artery, consistent with early plaque formation. The arrows show a lesion in the large first diagonal branch with both noncalcified ("soft") and calcified (white dot) components.}
\end{figure}

\section*{REFERENCES}


3. Tuzcu EM, Hobs RE, Rincon G, et al. Occult and frequent transmission of atherosclerotic coronary disease with cardiac transplanta-


20. Libby P. Current concepts of the pathogenesis of the acute coro-


29. Nissen SE, Yock P. Intravascular ultrasound: novel pathophysiologi-


32. Rumberger JA, Simons DB, Fitzpatrick LA, Sheedy PF, Schwartz RS. Coronary artery calcium area by electron-beam computed tomog-


35. Schoenhagen P, Tuzcu EM. Coronary artery calcification and end-

36. Callister TQ, Raggi P, Cool B, Lippolis NJ, Russo DJ. Effect of HMG-CoA reductase inhibitors on coronary artery disease by electron-


38. Scharl M, Bocksch W, Koschyk DH, et al. Use of intravascular ultra-
sound to compare effects of different strategies of lipid-lowering therapy on plaque volume and composition in patients with coro-

39. O’Rourke RA, Brundage BH, Froelicher VF, et al. American College of Cardiology/American Heart Association expert consensus docu-


41. Schroeder S, Kopp AF, Baumbach A, et al. Noninvasive characteri-


ADDRESS: E. Murat Tuzcu, MD, Department of Cardiovascular Medicine, F25, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail tuzcue@ccf.org.